Abstract 2127: Synergistic effect of carboxyl-modified magnetic nanoparticles and docetaxel on prostate cancer cells in vitro.

Abstract

Abstract Chemotherapy is used for castration-resistant prostate cancer as one of treatment options. In this regard, docetaxel-based chemotherapy has been shown to improve the quality of life in patients with the advanced disease. However, this needs to be improved because of limitations by lack of specificity, systemic toxicity, and progression of docetaxel-resistance. Nanotechnology has served a new role in medical sciences by a variety of nanotechnology platforms, leading to therapy and diagnostics. Among these platforms, magnetic nanoparticles (Fe3O4) have potential applications in drug delivery, cancer diagnosis and therapy. We have shown that magnetic nanoparticles (MgNPs) would modify the effect of chemotherapy in cancer cells. In this study, we analyzed the combined effect of docetaxel and carboxyl-modified magnetic nanoparticles (MgNPs-COOH) on a prostate cancer cell line, DU145 and their mechanisms compared with the effect of MgNPs and docetaxel. The combination of docetaxel and MgNPs/MgNPs-COOH more effectively inhibited cancer cell growth and induced apoptosis. While only MgNPs produced reactive oxygen species (ROS) and inhibited cancer cell growth slightly, MgNPs-COOH did neither produce ROS nor inhibit cancer cell growth. In addition, these two MgNPs appear to inhibit the different cellular pathways involving apoptosis and inflammation. These results suggest that MgNPs-COOH may induce different responses compared with MgNPs, and result in favorable development of current chemotherapy for the advanced disease and leading to new tumor ablation therapies. Citation Format: Masatoshi Watanabe, Akiko Sato, Daiki Okamoto, Daisuke Kurioka, Hitoshi Ishiguro, Hiroji Uemura, Yoshinobu Kubota. Synergistic effect of carboxyl-modified magnetic nanoparticles and docetaxel on prostate cancer cells in vitro. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2127. doi:10.1158/1538-7445.AM2013-2127